Conditions: Schizophrenia
Keywords: Schizophrenia Appetite Oxytocin
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 24
Healthy volunteers: no

Brief summary:
The objective of this study is to test a single dose of intranasal oxytocin, compared to placebo, in a within subjects, crossover design, to see if oxytocin will improve satiety signaling (behaviorally and/or by self report) compared to placebo. If this single dose pilot paradigm shows an increase in satiety, it may be tested in follow-up studies as a prevention or treatment for weight gain and overeating in people with schizophrenia.

Detailed description:

Arms:
arm 1: Each participant will receive intranasal oxytocin 24IU or intranasal saline 24IU in random order. All results will be reported by treatment, the sample is too small for order effects. arm 2: Each participant will receive intranasal oxytocin 24IU or intranasal saline 24IU in random order. All results will be reported by treatment, the sample is too small for order effects.

Interventions: intervention 1: Oxytocin intervention 2: Placebo
Intervention descriptions: intervention 1: Single dose intranasal oxytocin (24 IU) intervention 2: Placebo- Sugar pill

Protocol document: